IRAK4
Interleukin-1 receptor-associated kinase 4
As of the edition of 20 October 2026, IRAK4 (interleukin-1 receptor-associated kinase 4, UniProt Q9NWZ3) has 7 drugs tested at it and 8 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9NWZ3
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 98
- Disease areas
- Skin and connective tissue; Cancer; Immune system; Blood and lymph; Digestive system; Bones, joints and muscles; Infections; Inherited and neonatal
- Registered trials of its drugs
- 35
Drugs at this target
| Status | Count |
|---|---|
| Active | 2 |
| Stopped | 5 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Emavusertib | Stopped | Phase 2 | none listed |
| Zimlovisertib | Stopped | Phase 2 | none listed |
| KT-474 | Stopped | Phase 2 | none listed |
| Nacresertib | Active | Phase 1 | none listed |
| Edecesertib | Stopped | Phase 2 | none listed |
| OD-07656 | Active | Phase 2 | none listed |
| TQH3821 | Stopped | Phase 2 | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Engaged | 5 |
| Total on the list | 8 |
| Company | Route |
|---|---|
| Chia Tai Tianqing Pharmaceutical | Route A |
| Sanofi | Route A |
| Gilead Sciences | Route A |
The other 5 companies at IRAK4
In the product8 companies in all; 5 are not named here, and no score is.
See the 8 companies at IRAK4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.